Overview

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Status:
Recruiting
Trial end date:
2024-02-07
Target enrollment:
Participant gender:
Summary
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharma Global FZE